Purpose
A promise that
empowers
2023-2024
Milestones
Business
- Delivered full-year 2023 revenues of $305.2 million, exceeding upper end of increased guidance range
- Reported positive topline data from Phase 3 ARISE study of ARIKAYCE in MAC lung disease patients who had not started antibiotics
- Completed enrollment in Phase 3 ASPEN study of brensocatib in bronchiectasis
- Initiated Phase 2 BiRCh study of brensocatib in chronic rhinosinusitis without nasal polyps (CRSsNP)
- Completed enrollment in Phase 2 study of TPIP in PH-ILD
- Unveiled new research platforms and capabilities and advanced more than 30 pre-clinical development programs
- Announced collaboration with Google Cloud to harness the power of AI for drug discovery, development, and commercialization
- Became founding sponsor of the COPD Foundation’s Bronchiectasis and NTM Care Center Network to facilitate access to care and support for patients across the U.S.
Culture
- Nearly 1,000 employees around the globe
- No. 1 Science Top Employer for third year in a row
- U.S. Great Place to Work Certification for third year in a row
- No. 1 on 2023 Best Workplaces in BioPharma™, Small and Medium list
- No. 7 on 2023 Best Workplaces for Millennials™, Small and Medium list
- No. 8 on 2023 Best Workplaces for Women™, Small and Medium list
- No. 1 Best Investor/Analyst Event and No. 2 Best IR Team by Institutional Investor
- WELL Health-Safety Rating at our U.S. headquarters, reflecting our commitment to the well-being of everyone who enters our office
Donna is a patient living with bronchiectasis who has been compensated for her time.
Donna first realized something was wrong with her lungs in 2010, when she coughed up blood after accidentally inhaling a bit of dust. In pain and alarmed by the blood, she visited the ER and was told she had double pneumonia. She felt fine for a few years after that, but in 2017 began to experience pneumonia frequently; at one point, she had to be rushed to the ER with a pulse oxygen saturation level of 83%.
“When I was initially diagnosed, I cried for a month and then decided I’m going to fight. Today, I’m helping others be their own advocate and learn how to live with bronchiectasis. I’m giving them the information I wish I had had, and helping them understand that they’ll find their own way.”
Sue is an ARIKAYCE patient who has been compensated for her time.
As a retired art teacher who loved gardening and hiking with her husband, Darrell, Sue thought she was the picture of good health. So she was shocked when, after a trip down her rural driveway to pick up the mail, she became short of breath, started coughing severely, and coughed up blood. She visited the emergency room, where a CT scan showed possible bronchiectasis, and was sent to see a pulmonologist and an infectious disease (ID) specialist. The ID physician recommended a sputum sample, which showed that Sue was positive for MAC lung disease.
“When I was diagnosed with this disease I had never heard of, I was just stunned. It was a daunting time but I got through it by leaning on my support team, including my husband, my doctor, and others living with MAC.”
Next Section